Anesticap Special Precautions

In patients with cardiac, respiratory, renal or hepatic impairment or in elderly, debilitated, hypovolaemic or epileptic patients or patients with disorders of consciousness ANESTICAP 1% MCT/LCT should be administered with caution and a reduced administration rate (see DOSAGE & ADMINISTRATION).
Cardiac, circulatory or pulmonary insufficiency and hypovolaemia should be compensated before administration of ANESTICAP 1% MCT/LCT.
Before anesthesia of an epileptic patient, it should be checked that the patient has received the anti-epileptic treatment. Administration of Propofol in epileptic patients may also increase the risk of seizure.
ANESTICAP 1% MCT/LCT should not be administered in patients with advanced cardiac failure or other severe myocardial disease except with extreme caution and intensive monitoring.
The intravenous administration of an anticholinergic agent before induction, or during maintenance of anesthesia should be considered, especially in situations where vagal tone is likely to predominate, or when ANESTICAP 1% MCT/LCT is used in conjunction with other agents likely to cause a bradycardia.
Use is not recommended with electroconvulsive therapy.
Special care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used with caution. If patients receive parenteral nutrition, it is necessary to take account of the amount of lipid infusion as part of the ANESTICAP 1% MCT/LCT formulation: 1.0 mL ANESTICAP 1% MCT/LCT contains 0.1 g of fat.
Lipids should be monitored in the Intensive Care Unit treatment after 3 days.
Due to a higher dosage in patients with severe overweight the risk of haemodynamic effects on the cardiovascular system should be taken into consideration.
Special care should be recognized in patients with a high intracranial pressure and a low mean arterial pressure as there is a risk of a significant decrease of the intracerebral perfusion pressure.
To reduce pain on the injection site during induction of anesthesia with ANESTICAP 1% MCT/LCT, lidocain can be injected prior to the Propofol emulsion.
Dilutions with lidocain solution must not be used in patients with hereditary acute porphyria.
For sedation in adult patients, ANESTICAP 1% MCT/LCT must be given only by these physicians trained in anesthesia or intensive care.
ANESTICAP 1% MCT/LCT should not be administered by the persons conducting the diagnostic or surgical procedure.
ANESTICAP 1% MCT/LCT is not recommended for use in pediatric patients for ICU (Intensive Care Unit) sedation.
Although no causal relationship has been established, use of Propofol for sedation in children has led to serious and sometimes fatal adverse events. These events observed from spontaneous reports of unlicensed use were seen most often in children with respiratory tract infections given doses in excess of those recommended for adults.
Aseptic must be maintained for both ANESTICAP 1% MCT/LCT and infusion equipment throughout the infusion period. Co-administration of other drugs or fluids added to the ANESTICAP 1% MCT/LCT infusion line must occur close to the cannula site.
ANESTICAP 1% MCT/LCT must not be administered via a microbiological filter.
ANESTICAP 1% MCT/LCT and any infusion equipment containing ANESTICAP 1% MCT/LCT are for single administration in an individual patient.
Effects on driving ability and use machines: After administration of ANESTICAP 1% MCT/LCT, the patient should be kept under observation for an appropriate period of time. The patient should be instructed not to drive, operate machinery, or work in potentially hazardous situations. The patient should not be allowed to go home unaccompanied, and should be instructed to avoid consumption of alcohol.
Use in Pregnancy and Lactation: ANESTICAP 1% MCT/LCT must not be used during pregnancy, breast feeding and obstetrics (except abortion).